Clarius Group LLC Has $3.42 Million Stock Holdings in Johnson & Johnson $JNJ

Clarius Group LLC decreased its position in Johnson & Johnson (NYSE:JNJ) by 25.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 18,422 shares of the company’s stock after selling 6,436 shares during the quarter. Clarius Group LLC’s holdings in Johnson & Johnson were worth $3,416,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in JNJ. Evolution Wealth Management Inc. bought a new position in Johnson & Johnson during the 2nd quarter worth $27,000. Semmax Financial Advisors Inc. grew its stake in shares of Johnson & Johnson by 55.0% in the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after acquiring an additional 72 shares in the last quarter. GFG Capital LLC bought a new position in Johnson & Johnson during the second quarter worth about $35,000. 1248 Management LLC acquired a new stake in Johnson & Johnson in the 1st quarter worth about $48,000. Finally, Vermillion & White Wealth Management Group LLC boosted its holdings in Johnson & Johnson by 66.4% in the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 376 shares of the company’s stock valued at $57,000 after purchasing an additional 150 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on JNJ. Johnson Rice set a $190.00 price target on shares of Johnson & Johnson and gave the company a “hold” rating in a research report on Wednesday, October 22nd. Loop Capital set a $190.00 price objective on Johnson & Johnson in a research note on Wednesday, October 22nd. Daiwa Capital Markets upgraded Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 target price for the company in a research report on Monday, October 20th. JPMorgan Chase & Co. raised their price target on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 16th. Finally, Citigroup boosted their price target on Johnson & Johnson from $215.00 to $232.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. Four analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $210.25.

Johnson & Johnson Price Performance

Shares of JNJ opened at $207.29 on Tuesday. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The stock has a market cap of $499.43 billion, a PE ratio of 20.01, a PEG ratio of 2.24 and a beta of 0.36. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $215.18. The business has a 50-day simple moving average of $198.43 and a two-hundred day simple moving average of $179.75.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The company had revenue of $24.02 billion for the quarter. Analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th were issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date was Tuesday, November 25th. Johnson & Johnson’s payout ratio is 50.19%.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.